Limula SA is a Life Science start-up based in Lausanne, Switzerland. Limula was established with the explicit mission to help bring the most personalised treatments to patients in need, at reasonable cost, wherever they are. Limula provides a proprietary platform that performs all steps of CAR T-cell manufacturing in a sequence and in a single device, using end-to-end automation and integrated process analytics. Our novel bioreactor design increases product quality and production capacity by reducing complexity, footprint, hands-on time and run cost. Our innovative solution supports the production of personalised cancer treatments on demand and at scale, directly at the point of care.
For conference production and speaking opportunites: